Short information on the Brain Center Berlin (BCB)

The foundation of the BCB in 2004 was triggered by the need for a new organizational structure to enable innovative, practice-focussed clinical research. Effective research should be facilitated by avoiding the mass of red tape and time consuming logistics in much larger institutions.

Research of the BCB will focus on human brain function and disorders of such functions. This implies the development and application of routine procedures in diagnostic and treatment as well as a concept for early diagnostics and prevention of common disorders. The final goal is reduction of the burden and the costs of such illnesses.

As to disorders of the normal development of the necessary skills children and adolescents we offer a comprehensive spectrum of programmes for detailed assessment and intervention.

On the basis of long-term clinical observations we are interested in the development of new indications for approved drugs.

The BCB is a Limited Liability Company. The companions decide on projects in research and development. Decisions are essentially steered by the scientific advisory board (see below).

At present, the activities of BCB focus primarily on attention deficit disorder (ADHS) and Alzheimer's disease (DAT).

In this context, a special interest relates to neurophysiological processes and the dynamics of their regulation. A special procedure, called "Ipsative Trend Assessment" (ITA) has been developed to study EEG changes in serial assessments of neurodegenerative processes (8). The latter method will be used to investigate the efficacy of a preventive screening for DAT which will include a prophylactic treatment of subjects with a trend of declining mental functions (negative scores for the pre/post ITA-differences) with a statin.

Another focus is the systematic study of the effects of non-pharmacological body-focussed treatments on various psychiatric disorders. ITA will be used to investigate subtle changes of the level of CNS organization by Manual Somatointegrative Therapy (Slow stroke-massage) in patients with either depressive syndromes or Posttraumatic stress disorder (PTSD).


MEMBERS OF THE SCIENTIFIC ADVISORY BOARD:
Prof. Dr. med. R. Ferszt
(Neurology, Psychiatry, Neuropathology, Gerontopsychiatry)
Dr. rer. med. T. Fischmann
(Psychoanalysis, Psychophysiology)
Prof. Dr. phil. Dr. h.c. H. Hörz
(Philosophy, President of the Leibnitz-Society)
Prof. Dr. med. S. Kanowski
(Neurology, Psychiatry, Gerontopsychiatry)
Prof. Dr. P.F. Matthiessen
(Neurology, Psychiatry, Medicinal Theory of Cognition, Joint Hospital Herdecke)
W. Schlosser
(Expert for the IT-unit, Hard- and Softwaresolutions)
Prof. Dr. rer. nat. Dr. h.c. mult. H.-J. Treder
(Theoretical Physics, General Theory of Cognition)

Contact:
Dr. Wolfgang Droll
droll@geah.de